ABVC BioPharma, Inc.
ABVC
$1.33
$0.021.53%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -200.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -200.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -200.00% | |||
| SG&A Expenses | -29.06% | 12.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -59.09% | |||
| Total Operating Expenses | -28.37% | 11.88% | |||
| Operating Income | 47.43% | -156.51% | |||
| Income Before Tax | 55.67% | -196.22% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | 55.67% | -196.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -48.02% | 508.54% | |||
| Net Income | 56.21% | -185.83% | |||
| EBIT | 47.43% | -156.51% | |||
| EBITDA | 47.52% | -157.29% | |||
| EPS Basic | 57.46% | -168.84% | |||
| Normalized Basic EPS | 45.15% | -106.69% | |||
| EPS Diluted | 58.33% | -174.44% | |||
| Normalized Diluted EPS | 45.15% | -106.69% | |||
| Average Basic Shares Outstanding | 2.89% | 6.35% | |||
| Average Diluted Shares Outstanding | 2.89% | 6.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||